E-BASE Drug Patent Profile
✉ Email this page to a colleague
When do E-base patents expire, and when can generic versions of E-base launch?
E-base is a drug marketed by Barr and is included in three NDAs.
The generic ingredient in E-BASE is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for E-base
A generic version of E-BASE was approved as erythromycin by TORRENT on July 6th, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for E-BASE?
- What are the global sales for E-BASE?
- What is Average Wholesale Price for E-BASE?
Summary for E-BASE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 103 |
| Patent Applications: | 4,160 |
| DailyMed Link: | E-BASE at DailyMed |
US Patents and Regulatory Information for E-BASE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Barr | E-BASE | erythromycin | TABLET, DELAYED RELEASE;ORAL | 063028-001 | May 15, 1990 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Barr | E-BASE | erythromycin | TABLET, DELAYED RELEASE;ORAL | 063086-001 | May 15, 1990 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Barr | E-BASE | erythromycin | TABLET, DELAYED RELEASE;ORAL | 062999-001 | Nov 25, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
